JAM
SRPT icon

JW Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

JW Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-17,974
Closed -$351K – 43
2016
Q1 		$351K Buy
17,974
+10,000
+125% +$175K 0.23% 29
2015
Q4 		$308K Hold
7,974
– – 0.11% 31
2015
Q3 		$256K Buy
7,974
+75
+0.9% +$2.54K 0.09% 43
2015
Q2 		$240K Buy
+7,899
New +$162K 0.07% 44
2015
Q1 		– Sell
-6,000
Closed -$87K – 52
2014
Q4 		$87K Buy
+6,000
New +$102K 0.07% 46

Other funds holding SRPT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JW Asset Management's SRPT Position: Q2 2016 in Review

JW Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2016, closing a stake of 17,974 shares — an estimated $351K sold.

JW Asset Management first reported a position in SRPT in Q4 2014 and held it in 5 quarters. The position peaked at $351K in Q1 2016. 148 funds tracked by Wall St. Rank hold SRPT as of Q2 2016.

  • JW Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2016 after selling out during the quarter.
  • JW Asset Management sold 17,974 Sarepta Therapeutics shares in Q2 2016, an estimated $351K.
  • JW Asset Management first reported a position in Sarepta Therapeutics in Q4 2014 and held it in 5 quarters.
  • JW Asset Management's Sarepta Therapeutics position peaked at $351K in Q1 2016.
  • 148 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2016.

Based on JW Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.